688098 申联生物
午间休市 03-02 11:29:35
资讯
新帖
简况
股市必读：申联生物发布2025年度业绩快报，亏损0.191亿元
证券之星 · 03:18
股市必读：申联生物发布2025年度业绩快报，亏损0.191亿元
每周股票复盘：申联生物（688098）2025年净亏1909万同比减亏57.33%
证券之星 · 03-01 02:50
每周股票复盘：申联生物（688098）2025年净亏1909万同比减亏57.33%
申联生物控股世之源转型发展“人药”，目标公司尚未盈利
新京报 · 02-25
申联生物控股世之源转型发展“人药”，目标公司尚未盈利
动保业务颓势难改，申联生物跨界掘金人用创新药，续亏之下双主业谋变待考
中金财经 · 02-25
动保业务颓势难改，申联生物跨界掘金人用创新药，续亏之下双主业谋变待考
申联生物最新公告：拟2.37亿元收购世之源控股权并开展创新药业务
证券之星 · 02-24
申联生物最新公告：拟2.37亿元收购世之源控股权并开展创新药业务
每周股票复盘：申联生物（688098）现2710.22万元大宗交易
证券之星 · 02-15
每周股票复盘：申联生物（688098）现2710.22万元大宗交易
2月9日申联生物现2710.22万元大宗交易
证券之星 · 02-09
2月9日申联生物现2710.22万元大宗交易
股市必读：1月30日申联生物发布公告，股东减持710.4万股
证券之星 · 02-02
股市必读：1月30日申联生物发布公告，股东减持710.4万股
每周股票复盘：申联生物（688098）股东减持710.4万股
证券之星 · 02-01
每周股票复盘：申联生物（688098）股东减持710.4万股
1月30日申联生物发生1笔大宗交易 成交金额2710.4万元
证券之星 · 01-30
1月30日申联生物发生1笔大宗交易 成交金额2710.4万元
申联生物（688098）披露取得《兽药GMP证书》和《兽药生产许可证》公告，1月26日股价上涨2.71%
证券之星 · 01-26
申联生物（688098）披露取得《兽药GMP证书》和《兽药生产许可证》公告，1月26日股价上涨2.71%
股市必读：申联生物（688098）预计2025年全年扣非后净利润亏损约2350万元
证券之星 · 01-26
股市必读：申联生物（688098）预计2025年全年扣非后净利润亏损约2350万元
每周股票复盘：申联生物（688098）预计2025年净亏2000万元
证券之星 · 01-25
每周股票复盘：申联生物（688098）预计2025年净亏2000万元
申联生物（688098）披露2025年年度业绩预告，1月23日股价上涨0.1%
证券之星 · 01-23
申联生物（688098）披露2025年年度业绩预告，1月23日股价上涨0.1%
申联生物(688098.SH)发预亏，预计2025年度归母净亏损2000万元
智通财经 · 01-23
申联生物(688098.SH)发预亏，预计2025年度归母净亏损2000万元
申联生物：董事、高级管理人员离任
证券日报网 · 2025-12-28
申联生物：董事、高级管理人员离任
申联生物：拟续聘容诚会计师事务所为2025年度审计机构
证券日报网 · 2025-12-28
申联生物：拟续聘容诚会计师事务所为2025年度审计机构
申联生物（688098）披露股东一致行动关系终止暨权益变动触及5%整数倍的提示性公告，12月22日股价上涨1.22%
证券之星 · 2025-12-22
申联生物（688098）披露股东一致行动关系终止暨权益变动触及5%整数倍的提示性公告，12月22日股价上涨1.22%
申联生物(688098.SH)联营公司世之源获艾滋病单抗发明专利
智通财经网 · 2025-12-19
申联生物(688098.SH)联营公司世之源获艾滋病单抗发明专利
12月19日申联生物发生1笔大宗交易 成交金额1806.64万元
证券之星 · 2025-12-19
12月19日申联生物发生1笔大宗交易 成交金额1806.64万元
暂无数据
公司概况
公司名称：
申联生物医药(上海)股份有限公司
所属行业：
医药制造业
上市日期：
2019-10-28
主营业务：
申联生物医药(上海)股份有限公司的主营业务是涵盖动物预防、治疗及诊断生物产品的研发、生产和销售。公司的主要产品是系列猪、牛羊口蹄疫疫苗、猪圆环病毒2型亚单位疫苗、牛结节性皮肤病灭活疫苗及系列兽医诊断制品。公司于2024年荣获第七届中国(上海)国际发明创新展览会金奖2项。
发行价格：
8.80
{"stockData":{"symbol":"688098","market":"SH","secType":"STK","nameCN":"申联生物","latestPrice":9.43,"timestamp":1772422175000,"preClose":9.7,"halted":0,"volume":3051077,"delay":0,"changeRate":-0.0278,"floatShares":411000000,"shares":411000000,"eps":-0.0739,"marketStatus":"午间休市","change":-0.27,"latestTime":"03-02 11:29:35","open":9.63,"high":9.63,"low":9.26,"amount":28806700,"amplitude":0.0381,"askPrice":9.43,"askSize":16,"bidPrice":9.4,"bidSize":28,"shortable":0,"etf":0,"ttmEps":-0.0739,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772427600000},"marketStatusCode":3,"adr":0,"adjPreClose":9.7,"symbolType":"stock_kcb","openAndCloseTimeList":[[1772415000000,1772422200000],[1772427600000,1772434800000]],"highLimit":10.67,"lowLimit":8.73,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":410644000,"isCdr":false,"pbRate":2.83,"roa":"--","roe":"0.02%","epsLYR":-0.11,"committee":0.544741,"marketValue":3872000000,"turnoverRate":0.0074,"status":1,"floatMarketCap":3872000000},"requestUrl":"/m/hq/s/688098/tweets","defaultTab":"tweets","newsList":[{"id":"2616987629","title":"股市必读：申联生物发布2025年度业绩快报，亏损0.191亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616987629","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616987629?lang=zh_cn&edition=full","pubTime":"2026-03-02 03:18","pubTimestamp":1772392693,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，申联生物报收于9.7元，上涨1.68%，换手率0.83%，成交量3.4万手，成交额3281.78万元。业绩披露要点业绩快报申联生物近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润亏损0.191亿元，同比增长57.33%。公司公告汇总2025年度业绩快报公告申联生物发布2025年度业绩快报，营业总收入28,826.65万元，同比下降4.99%；归属于母公司所有者的净利润为-1,909.07万元，较上年减亏57.33%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200001496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"gpt_icon":0},{"id":"2616459938","title":"每周股票复盘：申联生物（688098）2025年净亏1909万同比减亏57.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616459938","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616459938?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:50","pubTimestamp":1772304618,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，申联生物报收于9.7元，较上周的9.66元上涨0.41%。本周，申联生物2月25日盘中最高价报10.34元。本周关注点业绩披露要点：申联生物2025年净亏1909.07万元，同比减亏57.33%。业绩披露要点申联生物近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润亏损0.191亿元，同比增长57.33%。营业总收入28,826.65万元，同比下降4.99%；归属于母公司所有者的净利润为-1,909.07万元，较上年减亏57.33%。一致行动人上海申源启航出资7,995.6392万元取得世之源10.35%股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"gpt_icon":0},{"id":"2614805460","title":"申联生物控股世之源转型发展“人药”，目标公司尚未盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2614805460","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614805460?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:28","pubTimestamp":1772026080,"startTime":"0","endTime":"0","summary":"本次交易完成后，申联生物能够控制世之源51%股权的表决权，世之源成为申联生物的控股孙公司，纳入合并报表范围。申联生物表示，公司通过收购世之源控股权，整合其在创新药领域的核心研发能力与技术平台体系，强化人用药板块的研发管线与产业化基础。2021年以来，申联生物归母净利润持续下滑，2024年陷入亏损。2025年业绩预告显示，申联生物预计实现归属于母公司所有者的净利润约-2000万元。","market":"sh","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/2/wangl8820262251659242922617.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/2/wangl8820262251659242922617.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1772026117168567.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1772026117168567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["688098","BK0239"],"gpt_icon":0},{"id":"2614092437","title":"动保业务颓势难改，申联生物跨界掘金人用创新药，续亏之下双主业谋变待考","url":"https://stock-news.laohu8.com/highlight/detail?id=2614092437","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614092437?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:23","pubTimestamp":1772007786,"startTime":"0","endTime":"0","summary":"标的世之源手握三款分别针对病毒感染和过敏免疫领域的在研创新药，申联生物试图通过收购切入人用创新药赛道，剑指“人用药品+ 动物保健”双主业发展格局。收购完成后，申联生物将形成“人用药品”与“动物保健”双主业协同发展的新格局。收购世之源，申联生物寄予一定厚望，但也面临重重挑战。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260225/32026374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","BK1574","159992","06978","BK0239","688098"],"gpt_icon":0},{"id":"2613794846","title":"申联生物最新公告：拟2.37亿元收购世之源控股权并开展创新药业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2613794846","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613794846?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:40","pubTimestamp":1771926009,"startTime":"0","endTime":"0","summary":"申联生物(688098.SH)公告称，公司拟使用2.37亿元自有资金及自筹资金，通过全资子公司上海本天成生物医药有限公司以股权转让及增资方式取得扬州世之源生物科技有限责任公司的控股权。交易完成后，本天成及其一致行动人将合计持有世之源51%的股权，世之源成为公司的控股孙公司，纳入上市公司合并报表范围。公司将全面开展创新药业务，形成“人用药品”与“动物保健”双主业协同发展的新格局。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400033461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","159992","BK0239","BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2611145956","title":"每周股票复盘：申联生物（688098）现2710.22万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2611145956","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611145956?lang=zh_cn&edition=full","pubTime":"2026-02-15 02:17","pubTimestamp":1771093030,"startTime":"0","endTime":"0","summary":"截至2026年2月13日收盘，申联生物报收于9.66元，较上周的9.35元上涨3.32%。本周，申联生物2月10日盘中最高价报9.87元。交易信息汇总2月9日申联生物现2710.22万元大宗交易。股本股东变化股东增减持2月9日申联生物发布公告《申联生物:关于持股5%以上股东权益变动触及1%刻度及减持计划完成暨减持股份结果公告》，其股东UNITED BIOMEDICAL,INC.于2026年2月9日合计减持307.98万股，占公司目前总股本的0.75%，变动期间该股股价上涨3.32%，截止2月9日收盘报9.66元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021500000716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"gpt_icon":0},{"id":"2610366635","title":"2月9日申联生物现2710.22万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2610366635","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610366635?lang=zh_cn&edition=full","pubTime":"2026-02-09 17:32","pubTimestamp":1770629536,"startTime":"0","endTime":"0","summary":"证券之星消息，2月9日申联生物发生大宗交易，交易数据如下：大宗交易成交价格8.8元，相对当日收盘价折价8.9%，成交307.98万股，成交金额2710.22万元，买方营业部为中信建投证券股份有限公司广西分公司，卖方营业部为国信证券股份有限公司上海陆家嘴环路证券营业部。近三个月该股共发生3笔大宗交易，合计成交8.21万手，折价成交3笔。截至2026年2月9日收盘，申联生物报收于9.66元，上涨3.32%，换手率1.06%，成交量4.37万手，成交额4191.05万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900022461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"gpt_icon":0},{"id":"2608437889","title":"股市必读：1月30日申联生物发布公告，股东减持710.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608437889","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608437889?lang=zh_cn&edition=full","pubTime":"2026-02-02 03:39","pubTimestamp":1769974751,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，申联生物报收于9.53元，上涨1.49%，换手率1.24%，成交量5.11万手，成交额4838.44万元。大宗交易1月30日申联生物发生1笔大宗交易，成交金额2710.4万元。股本股东变化股东增减持1月30日申联生物发布公告，股东UNITED BIOMEDICAL, INC.于2025年12月4日至2026年1月30日间合计减持710.4万股，占公司总股本的1.73%。其中通过集中竞价减持197.104万股，通过大宗交易减持513.3万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"gpt_icon":0},{"id":"2608077247","title":"每周股票复盘：申联生物（688098）股东减持710.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608077247","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608077247?lang=zh_cn&edition=full","pubTime":"2026-02-01 03:14","pubTimestamp":1769886852,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，申联生物报收于9.53元，较上周的9.97元下跌4.41%。本周，申联生物1月26日盘中最高价报10.44元。交易信息汇总1月30日申联生物发生1笔大宗交易，成交金额2710.4万元。股本股东变化1月30日申联生物发布公告，股东UNITED BIOMEDICAL,INC.于2025年12月4日至2026年1月30日间合计减持710.4万股，占公司目前总股本的1.73%。本次权益变动后，UBI持股比例由10.00%降至8.27%。减持计划尚未实施完毕。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100001052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"gpt_icon":0},{"id":"2607901595","title":"1月30日申联生物发生1笔大宗交易 成交金额2710.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607901595","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607901595?lang=zh_cn&edition=full","pubTime":"2026-01-30 17:41","pubTimestamp":1769766060,"startTime":"0","endTime":"0","summary":"证券之星消息，1月30日申联生物发生大宗交易，交易数据如下：大宗交易成交价格8.8元，相对当日收盘价折价7.66%，成交308万股，成交金额2710.4万元，买方营业部为中信建投证券股份有限公司广西分公司，卖方营业部为国信证券股份有限公司上海陆家嘴环路证券营业部。近三个月该股共发生2笔大宗交易，合计成交5.13万手，折价成交2笔。截至2026年1月30日收盘，申联生物报收于9.53元，上涨1.49%，换手率1.24%，成交量5.11万手，成交额4838.44万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000031226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"gpt_icon":0},{"id":"2606209249","title":"申联生物（688098）披露取得《兽药GMP证书》和《兽药生产许可证》公告，1月26日股价上涨2.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606209249","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606209249?lang=zh_cn&edition=full","pubTime":"2026-01-26 22:54","pubTimestamp":1769439256,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘，申联生物报收于10.24元，较前一交易日上涨2.71%，最新总市值为42.05亿元。该股当日开盘9.97元，最高10.44元，最低9.74元，成交额达1.29亿元，换手率为3.11%。申联生物医药（上海）股份有限公司兰州分公司近日通过兽药GMP验收，取得甘肃省农业农村厅核发的《兽药GMP证书》和《兽药生产许可证》。此次获证的生产线将用于生产猪伪狂犬病活疫苗、仔猪副伤寒活疫苗等产品，公司正申报相关兽药产品批准文号，推进产品上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600036948.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"gpt_icon":0},{"id":"2606265052","title":"股市必读：申联生物（688098）预计2025年全年扣非后净利润亏损约2350万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606265052","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606265052?lang=zh_cn&edition=full","pubTime":"2026-01-26 03:50","pubTimestamp":1769370619,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，申联生物报收于9.97元，上涨0.1%，换手率1.27%，成交量5.22万手，成交额5205.8万元。申联生物发布业绩预告，预计2025年全年归属净利润亏损约2000万元。公司公告汇总申联生物预计2025年度归属于母公司所有者的净利润约为-2,000万元，较上年同期亏损收窄约55%；扣除非经常性损益后的净利润约为-2,350万元，亏损收窄约51%。此外，投资参股并拟收购扬州世之源生物科技公司，布局人用创新药领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600001690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098"],"gpt_icon":0},{"id":"2606123750","title":"每周股票复盘：申联生物（688098）预计2025年净亏2000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606123750","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606123750?lang=zh_cn&edition=full","pubTime":"2026-01-25 03:35","pubTimestamp":1769283312,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，申联生物报收于9.97元，较上周的9.6元上涨3.85%。本周，申联生物1月21日盘中最高价报10.48元。申联生物当前最新总市值40.94亿元，在动物保健板块市值排名11/11，在两市A股市值排名4093/5182。本周关注点来自业绩披露要点：申联生物预计2025年归属净利润亏损约2000万元。公司公告汇总申联生物预计2025年度归属于母公司所有者的净利润约为-2,000万元，较上年同期亏损收窄约55%；扣除非经常性损益后的净利润约为-2,350万元，亏损收窄约51%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500001301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"gpt_icon":0},{"id":"2605409274","title":"申联生物（688098）披露2025年年度业绩预告，1月23日股价上涨0.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605409274","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605409274?lang=zh_cn&edition=full","pubTime":"2026-01-23 23:17","pubTimestamp":1769181432,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，申联生物报收于9.97元，较前一交易日上涨0.1%，最新总市值为40.94亿元。该股当日开盘9.9元，最高10.08元，最低9.89元，成交额达5205.8万元，换手率为1.27%。近日，申联生物披露《2025年年度业绩预告》。公告显示，公司预计2025年度归属于母公司所有者的净利润约为-2,000万元，较上年同期亏损收窄约55%；扣除非经常性损益后的净利润约为-2,350万元，亏损收窄约51%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300043956.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"gpt_icon":0},{"id":"2605420113","title":"申联生物(688098.SH)发预亏，预计2025年度归母净亏损2000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605420113","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605420113?lang=zh_cn&edition=full","pubTime":"2026-01-23 16:36","pubTimestamp":1769157413,"startTime":"0","endTime":"0","summary":"智通财经APP讯，申联生物 发布2025年年度业绩预告，预计2025年度实现归属于母公司所有者的净利润约-2,000万元，与上年同期相比，减少亏损约2,474万元，亏损幅度同比收窄约55%。报告期初，公司投资参股创新药公司扬州世之源生物科技有限责任公司，世之源正在开展创新药的临床研究并进行持续投入，对公司净利润造成一定影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688098"],"gpt_icon":0},{"id":"2594200402","title":"申联生物：董事、高级管理人员离任","url":"https://stock-news.laohu8.com/highlight/detail?id=2594200402","media":"证券日报网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594200402?lang=zh_cn&edition=full","pubTime":"2025-12-28 21:38","pubTimestamp":1766929080,"startTime":"0","endTime":"0","summary":"证券日报网讯12月28日，申联生物发布公告称，童光志因个人原因申请辞去公司董事职务，同时一并辞去在公司董事会下设的战略委员会、提名委员会中担任的委员职务，辞任后不在公司担任何职务；聂文豪因工作调整申请辞去公司副总经理职务，辞任后仍在公司担任董事一职，并在公司及子公司担任其他职务。2025年12月25日，公司召开职工代表大会，选举张震为公司第四届董事会职工代表董事。公司第四届董事会第六次会议选举职工代表董事张震先生为公司第四届董事会提名委员会委员和第四届董事会战略委员会委员。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-28/doc-inhekhin5618011.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-28/doc-inhekhin5618011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688098"],"gpt_icon":0},{"id":"2594122002","title":"申联生物：拟续聘容诚会计师事务所为2025年度审计机构","url":"https://stock-news.laohu8.com/highlight/detail?id=2594122002","media":"证券日报网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594122002?lang=zh_cn&edition=full","pubTime":"2025-12-28 21:38","pubTimestamp":1766929080,"startTime":"0","endTime":"0","summary":"证券日报网讯12月28日，申联生物发布公告称，公司拟续聘容诚会计师事务所(特殊普通合伙)为2025年度财务报告及内控审计机构，聘期一年，审计费用57万元，其中财务报告审计费45万元，较上年度下降6.25%，内控审计费12万元不变，该议案已获董事会通过，尚待股东会审议。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-28/doc-inhekhim0975767.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-28/doc-inhekhim0975767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688098"],"gpt_icon":0},{"id":"2593485213","title":"申联生物（688098）披露股东一致行动关系终止暨权益变动触及5%整数倍的提示性公告，12月22日股价上涨1.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593485213","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593485213?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:52","pubTimestamp":1766397174,"startTime":"0","endTime":"0","summary":"截至2025年12月22日收盘，申联生物报收于9.12元，较前一交易日上涨1.22%，最新总市值为37.45亿元。近日，申联生物发布关于股东一致行动关系终止暨权益变动触及5%整数倍的提示性公告。本次变动后，上述自然人股东合计持股比例由35.82%降至30.78%，触及5%整数倍权益变动披露标准。公告指出，各股东持股数量未发生变化，本次变动不触及要约收购，公司控制权未发生变更。此外，申太联将遵守相关减持规定，在六个月内不减持其所持股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200022571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688098","BK0239"],"gpt_icon":0},{"id":"2592616012","title":"申联生物(688098.SH)联营公司世之源获艾滋病单抗发明专利","url":"https://stock-news.laohu8.com/highlight/detail?id=2592616012","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592616012?lang=zh_cn&edition=full","pubTime":"2025-12-19 22:18","pubTimestamp":1766153894,"startTime":"0","endTime":"0","summary":"智通财经APP讯，申联生物 公告，公司联营公司扬州世之源生物科技有限责任公司于近日获得国家知识产权局颁发的“借由针对CD4之单克隆抗体介导竞争型HIV进入抑制之HIV感染的治疗和功能性治愈”的发明专利，此发明专利是关于针对CD4单克隆抗体、其组合物以及使用此组合物以预防、治疗和功能性治愈HIV感染的方法。因UB-421并非直接针对病毒基因，所以相较于当前市场上现有的治疗艾滋病药物，UB-421引起病毒耐药突变的概率较低，且具有免疫调节作用。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"申联生物(688098.SH)联营公司世之源获艾滋病单抗发明专利","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["688098","BK0239"],"gpt_icon":0},{"id":"2592150058","title":"12月19日申联生物发生1笔大宗交易 成交金额1806.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592150058","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592150058?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:47","pubTimestamp":1766137674,"startTime":"0","endTime":"0","summary":"证券之星消息，12月19日申联生物发生大宗交易，交易数据如下：大宗交易成交价格8.8元，相对当日收盘价折价2.33%，成交205.3万股，成交金额1806.64万元，买方营业部为中信建投证券股份有限公司广西分公司，卖方营业部为国信证券股份有限公司上海陆家嘴环路证券营业部。近三个月该股共发生1笔大宗交易，合计成交2.05万手，折价成交1笔。截至2025年12月19日收盘，申联生物报收于9.01元，上涨2.15%，换手率0.63%，成交量2.57万手，成交额2306.3万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900027352.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688098"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772422747952,"stockEarnings":[{"period":"1week","weight":0.0041},{"period":"1month","weight":0.0073},{"period":"3month","weight":0.0083},{"period":"6month","weight":-0.2165},{"period":"1year","weight":0.6899},{"period":"ytd","weight":0.0923}],"compareEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":0.0028},{"period":"3month","weight":0.0705},{"period":"6month","weight":0.079},{"period":"1year","weight":0.2287},{"period":"ytd","weight":0.0489}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"申联生物医药(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12388人(较上一季度增加30.87%)","perCapita":"33148股","listingDate":"2019-10-28","address":"上海市闵行区江川东路48号","registeredCapital":"41064万元","survey":" 申联生物医药(上海)股份有限公司的主营业务是涵盖动物预防、治疗及诊断生物产品的研发、生产和销售。公司的主要产品是系列猪、牛羊口蹄疫疫苗、猪圆环病毒2型亚单位疫苗、牛结节性皮肤病灭活疫苗及系列兽医诊断制品。公司于2024年荣获第七届中国(上海)国际发明创新展览会金奖2项。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"申联生物(688098)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供申联生物(688098)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"申联生物,688098,申联生物股票,申联生物股票老虎,申联生物股票老虎国际,申联生物行情,申联生物股票行情,申联生物股价,申联生物股市,申联生物股票价格,申联生物股票交易,申联生物股票购买,申联生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"申联生物(688098)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供申联生物(688098)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}